-
Science & technology
Science & technology
Novavax creates transformational vaccines that help address some of the world’s most pressing infectious diseases.
- Overview
- Our pipeline
- Matrix-M™ adjuvant
- Recombinant, protein-based nanoparticle vaccine
- Global vaccine approval/authorization map
COVID-19 UPDATESNovavax has demonstrated its ability to quickly produce viable vaccine candidates for emerging infectious diseases such as COVID-19.
-
Who we are
Who we are
We are a biotechnology company committed to help address serious infectious disease globally through the discovery, development, and delivery of innovative vaccines to patients around the world.
Build your future with usJoin other passionately curious people who are bringing innovative vaccines to the world
-
Insights
Insights
Novavax is committed to accelerating the development of new and promising vaccines by building on years of study and experience.
Novavax investigational COVID-19 vaccine (NVX-CoV2373)
Therapeutic area | Infectious disease | Status | Technology |
---|---|---|---|
Respiratory diseases | COVID-19 | Authorized* | Matrix-M™ adjuvant |
Therapeutic area
Respiratory diseases
Infectious disease
COVID-19
Status
Authorized*
Technology
Matrix-M™ adjuvant
About the candidate
NVX-CoV2373 is a protein-based vaccine targeting SARS-CoV-2, the virus that causes COVID-19. Recombinant technology is used to create vaccine protein antigens, which are arranged around a nanoparticle core and then formulated with Matrix-M™ adjuvant to create the ready-to-use NVX-CoV2373 vaccine. Recombinant technology is used to create vaccine nanoparticles, which are then mixed with Matrix-M™ adjuvant to create the ready-to-use NVX-CoV2373 vaccine. NVX-CoV2373 is still under investigation in the United States and is not authorized for use. For Global authorizations, please refer to the global vaccine authorization/approval map.
NVX-CoV2373 vaccine design
- 1
SARS-CoV-2 spike protein gene inserted into insect virus
The full-length, stabilized spike gene is engineered into baculovirus.
- 2
Sf9 cells infected
Recombinant baculovirus infects moth cells in the S. frugiperda (Sf9) expression system.
- 3
Spike gene enters Sf9 cell nucleus
Spike DNA is transcribed.
- 4
Sf9 cells produce spike proteins
Spike proteins are expressed in their native trimer conformation.
- 5
Nanoparticle formation
Spike protein trimers are harvested. Vaccine nanoparticles assemble as spike protein trimers arranged around a Polysorbate 80 (PS80) core.
- 6
Final vaccine
Vaccine nanoparticles are mixed with Matrix-MTM adjuvant to create ready-to-use NVX-CoV2373 vaccine.
Why it matters
COVID-19 continues to evolve around the world and is responsible for millions of deaths.1 Our NVX-CoV2373 vaccine candidate has been shown to produce robust, functional immune responses in diverse clinical trial populations.
Vaccines produced using Novavax' technology are stable at standard refrigeration temperatures, enabling NVX-CoV2373 to reach people around the world.
*Authorized for use in several countries.
- COVID-19 situation update worldwide, as of week 21, updated 3 June 2021. ECDC. Available at: https://www.ecdc.europa.eu/en/geographical-distribution-2019-ncov-cases [Accessed 3 Sept 2021].